Colombia Partners with 3PBIOVIAN to Develop First Domestic Biosimilar Cancer Drug
核心洞察
Colombia's National Cancer Institute has partnered with 3PBIOVIAN (搜索) to develop the country's first biosimilar monoclonal antibody for oncology treatment, marking a historic shift toward pharmaceutical independence.
The initiative aims to address Colombia's heavy dependence on imported biotechnological drugs and reduce costs for cancer treatments in a country recording over 117,000 new cancer cases annually.
The project involves full development from cell line creation to technology transfer, with manufacturing planned at Colombian facilities as part of a broader $365 million investment in biopharmaceutical infrastructure.
Colombia's National Cancer Institute (Instituto Nacional de Cancerología, INC) has signed a groundbreaking contract with 3PBIOVIAN (搜索), a leading Contract Development and Manufacturing Organization (CDMO), to develop the country's first biosimilar monoclonal antibody for oncology treatment. This partnership marks a historic milestone in Colombia's pharmaceutical policy, representing the nation's first domestic production of cancer drugs.
The agreement encompasses the complete development process, including cell line development, process and analytical method development, process scale-up, and technology transfer to Colombian facilities where manufacturing will ultimately take place to supply product for patient care. This comprehensive approach positions Colombia to achieve greater pharmaceutical independence in one of the most technologically challenging areas of drug manufacturing.
Addressing Critical Healthcare Needs
The initiative directly responds to Colombia's substantial cancer burden, with more than 117,000 new cancer cases recorded annually according to international incidence estimates. Cancer has become one of the leading causes of death in the country, claiming more than 45,000 lives each year. The most frequent types include breast, prostate, colon, stomach, and lung cancers, which account for a large share of diagnoses and associated mortality.
"We are proud to contribute to this project, which truly reflects 3PBIOVIAN (搜索)'s purpose: to enable global access to high-quality biopharmaceuticals," said Dámaso Molero, Group CEO of 3PBIOVIAN. "This collaboration reinforces our experience in mammalian development programs and our commitment to international partnerships that make a real impact on patients' lives."
Strategic Infrastructure Investment
The project is part of a broader initiative that began taking shape eight years ago and received formal resource allocation in 2025. The modernization includes an investment of 1.37 trillion pesos (approximately US$365 million) between 2026 and 2035, aimed at strengthening public or mixed infrastructure and technological development extending beyond cancer treatment.
This investment will enable the doubling of manufacturing capacity for hyperimmune sera and launch a small-scale production plant. The public initiative will also favor vaccine production, representing a clear effort to reactivate the technological, scientific, and industrial capacities that Colombia once possessed but lost over the years.
Reducing Import Dependence
Currently, Colombia faces strong dependence on imported medicines, particularly biotechnological products. Virtually all biosimilars used in the country are manufactured abroad and later marketed in the national market. This situation not only increases costs but also exposes the health system to potential supply problems and fluctuations in international prices.
The manufacture of monoclonal antibodies represents one of the greatest technological challenges in the pharmaceutical industry. Unlike traditional chemical drugs, these products require complex biological engineering processes, quality control, and clinical validation. Each stage, from cell culture to purification of the final product, must meet very strict international standards to guarantee patient safety.
Biosimilar Advantages
The drug being developed is a biosimilar, a version highly comparable to original biological medicines once their patents expire. Although they are not identical copies, they maintain the same level of efficacy, safety, and therapeutic quality. Various studies show that biosimilars can generate significant reductions in the price of biotechnological medicines, helping ease financial pressure on health systems.
In the Colombian case, the impact could be especially significant given that monoclonal antibodies are among the most expensive treatments in oncology, and their use has increased in recent years due to their effectiveness in targeted therapies against specific tumors.
Regional Impact Potential
For 3PBIOVIAN (搜索), the contract represents a significant milestone in strengthening its track record in full mammalian development, from cell line creation through industrial-scale process transfer. The company operates manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, providing comprehensive services from preclinical and clinical supply to large-scale commercial manufacturing.
Experts suggest that if the initiative successfully consolidates, Colombia could move toward creating its own biopharmaceutical industry, capable not only of supplying the domestic market but also exporting medicines to other Latin American countries. This development could position Colombia as a regional leader in biosimilar production and biotechnological innovation.
The project represents an innovative initiative driven by the ambition to expand access to affordable biologic medicines while strengthening Colombia's biotechnological sovereignty. The success will depend on the ability of public institutions to develop the necessary infrastructure and train scientific teams capable of sustaining production over time.